Selective anti-cancer agents as anti-aging drugs
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Recent groundbreaking discoveries have revealed that IGF-1, Ras, MEK, AMPK, TSC1/2, FOXO, PI3K, mTOR, S6K, and NFκB are involved in the aging process. This is remarkable because the same signaling molecules, oncoproteins and tumor suppressors, are well-known targets for cancer therapy. Furthermore, anti-cancer drugs aimed at some of these targets have been already developed. This arsenal could be potentially employed for anti-aging interventions (given that similar signaling molecules are involved in both cancer and aging). In cancer, intrinsic and acquired resistance, tumor heterogeneity, adaptation, and genetic instability of cancer cells all hinder cancer-directed therapy. But for anti-aging applications, these hurdles are irrelevant. For example, since anti-aging interventions should be aimed at normal postmitotic cells, no selection for resistance is expected. At low doses, certain agents may decelerate aging and age-related diseases. Importantly, deceleration of aging can in turn postpone cancer, which is an age-related disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“Temsirolimus and everolimus are approved for the treatment of renal cell carcinoma, breast cancer, progressive neuroendocrine tumors of pancreatic origin, and subependymal giant cell astrocytoma and are investigated for numerous other malignancies.(94-111) In addition, ATP-competitive inhibitors of the TOR kinase unde…”
BackgroundCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886 · cited 1×
“Rapamycin (sirolimus) and their analogs (everolimus, temsirolimus, and deforolimus) bind FKBP12 and thus inhibit mTOR complex 1 (mTORC1).(91-93) Rapalogs are anti-cancer drugs.”
BackgroundPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
mTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676 · cited 1×
“Pro-aging pathways are antagonized by gerosuppressors such as PTEN, AMPK, TSC1/2, sirtuins, and p53, which are also known as tumor suppressors.(47-63) The IGF-1/PI3K/mTOR/ S6K pathway is involved in age-related diseases such as atherosclerosis, organ hypertrophy, diabetic complications, and neurodegeneration.”
BackgroundMetformin improves healthspan and lifespan in mice
Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomes, A. P., Ward, T. M., Minor, R. K., Blouin, M.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3192 · Cited by 1,445
Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009) · Science · doi:10.1126/science.1177221 · Cited by 1,120 · cited 1×
“Pro-aging pathways are antagonized by gerosuppressors such as PTEN, AMPK, TSC1/2, sirtuins, and p53, which are also known as tumor suppressors.(47-63) The IGF-1/PI3K/mTOR/ S6K pathway is involved in age-related diseases such as atherosclerosis, organ hypertrophy, diabetic complications, and neurodegeneration.”
BackgroundDePinho, R. A. (2000) · Nature · doi:10.1038/35041694 · Cited by 951
Bhaumik, D., Scott, G. K., Schokrpur, S., Patil, C. K., Orjalo, A. V., Rodier, F., Lithgow, G. J., & Campisi, J. (2009) · Aging · doi:10.18632/aging.100042 · Cited by 500 · cited 1×
“The senescent phenotype is characterized by a large, flat cell morphology (hypertrophy), cellular hyperfunctions such as hypersecretion and proinflammation, and an increased lysosomal activity and lipid accumulation.(24-33) Senescent cells have increased levels of cyclin D1.”
BackgroundDazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460 · cited 1×
“The IGF-1/PI3K/mTOR/ S6K pathway is involved in age-related diseases such as atherosclerosis, organ hypertrophy, diabetic complications, and neurodegeneration.(64-72)”
BackgroundA murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 1×
“Numerous agents targeting mTOR, PI-3K, growth factor receptors, and related tyrosine kinases, Ras, Raf, and B-Raf, S6K, MEK1/2 have been tested to treat cancer.(73-86) The mTOR pathway is almost obligatorily activated in cancer.”
BackgroundAnisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M., et al. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.007 · Cited by 402
Georgakopoulou, E., Tsimaratou, K., Evangelou, K., Fernandez, M.-P., Zoumpourlis, V, Trougakos, I., Kletsas, D., Bartek, J., Serrano, M., & Gorgoulis, V. (2012) · Aging · doi:10.18632/aging.100527 · Cited by 390
Calorie restriction and cancer prevention: metabolic and molecular mechanisms
Longo, V. D., & Fontana, L. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.004 · Cited by 378
Metformin slows down aging and extends life span of female SHR mice
Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Tyndyk, M. L., Yurova, M. V., Kovalenko, I. G., Poroshina, T. E., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.17.6625 · Cited by 348
Coordination and communication between the p53 and IGF-1–AKT–TOR signal transduction pathways
Levine, A. J., Feng, Z., Mak, T. W., You, H., & Jin, S. (2006) · Genes & Development · doi:10.1101/gad.1363206 · Cited by 321 · cited 1×
“Noteworthy, p53 inhibits both cell cycle progression and the mTOR pathway.(18,36,87-90) Rapalogs (rapamycin and its analogs), which not only inhibit mTOR but also slow down the cell cycle, partially substitute for p53.”
BackgroundCoppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · cited 1×
“The senescent phenotype is characterized by a large, flat cell morphology (hypertrophy), cellular hyperfunctions such as hypersecretion and proinflammation, and an increased lysosomal activity and lipid accumulation.(24-33) Senescent cells have increased levels of cyclin D1.”
BackgroundMEK and the inhibitors: from bench to bedside
Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-27 · Cited by 291
Anisimov, V. N., Berstein, L. M., Popovich, I. G., Zabezhinski, M. A., Egormin, P. A., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Kovalenko, I. G., et al. (2011) · Aging · doi:10.18632/aging.100273 · Cited by 285 · cited 1×
“Anything that decelerates aging (for example calorie restriction and genetic manipulations) also postpones cancer.(170-175) This predicts that drugs that slow down the aging process will delay or prevent cancer.”
BackgroundThe choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.
Korotchkina, L. G., Leontieva, O. V., Bukreeva, E. I., Demidenko, Z. N., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Aging · doi:10.18632/aging.100160 · Cited by 278
Self-citationParadoxical suppression of cellular senescence by p53
Demidenko, Z. N., Korotchkina, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002298107 · Cited by 273
Self-citationHubackova, S., Krejcikova, K., Bartek, J., & Hodny, Z. (2012) · Aging · doi:10.18632/aging.100520 · Cited by 272 · cited 1×
“The senescent phenotype is characterized by a large, flat cell morphology (hypertrophy), cellular hyperfunctions such as hypersecretion and proinflammation, and an increased lysosomal activity and lipid accumulation.(24-33) Senescent cells have increased levels of cyclin D1.”
BackgroundBlagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100443 · Cited by 251 · cited 3×
“When the cell cycle is arrested, then overactivated MAPK and mTOR pathways cause cellular growth in size, leading to a senescent phenotype.(24) The senescent phenotype is characterized by a large, flat cell morphology (hypertrophy), cellular hyperfunctions such as hypersecretion and proinflammation, and an increased l…”
BackgroundSelf-citationMutations That Increase the Life Span of C. elegans Inhibit Tumor Growth
Pinkston, J. M., Garigan, D., Hansen, M., & Kenyon, C. (2006) · Science · doi:10.1126/science.1121908 · Cited by 242
p53, ROS and senescence in the control of aging
Vigneron, A., & Vousden, K. H. (2010) · Aging · doi:10.18632/aging.100189 · Cited by 221 · cited 1×
“Noteworthy, p53 inhibits both cell cycle progression and the mTOR pathway.(18,36,87-90) Rapalogs (rapamycin and its analogs), which not only inhibit mTOR but also slow down the cell cycle, partially substitute for p53.”
BackgroundHypoxia suppresses conversion from proliferative arrest to cellular senescence
Leontieva, O. V., Natarajan, V., Demidenko, Z. N., Burdelya, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205690109 · Cited by 169 · cited 1×
“Inhibitors of the PI-3K/mTOR pathway suppress geroconversion.(34-42) Thus, overstimulation of quiescent cells drives geroconversion.”
BackgroundSelf-citationSenescence-associated secretory phenotype favors the emergence of cancer stem-like cells
Cahu, J., Bustany, S., & Sola, B. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.183 · Cited by 160 · cited 1×
“The senescent phenotype is characterized by a large, flat cell morphology (hypertrophy), cellular hyperfunctions such as hypersecretion and proinflammation, and an increased lysosomal activity and lipid accumulation.(24-33) Senescent cells have increased levels of cyclin D1.”
BackgroundCaveolin-1 and Accelerated Host Aging in the Breast Tumor Microenvironment
Mercier, I., Camacho, J., Titchen, K., Gonzales, D. M., Quann, K., Bryant, K. G., Molchansky, A., Milliman, J. N., Whitaker-Menezes, D., Sotgia, F., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.03.017 · Cited by 96 · cited 1×
“Inhibitors of the PI-3K/mTOR pathway suppress geroconversion.(34-42) Thus, overstimulation of quiescent cells drives geroconversion.”
BackgroundSelf-citationHot topics in aging research: protein translation and TOR signaling, 2010
Kaeberlein, M., & Kennedy, B. K. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2010.00665.x · Cited by 66 · cited 1×
“Pro-aging pathways are antagonized by gerosuppressors such as PTEN, AMPK, TSC1/2, sirtuins, and p53, which are also known as tumor suppressors.(47-63) The IGF-1/PI3K/mTOR/ S6K pathway is involved in age-related diseases such as atherosclerosis, organ hypertrophy, diabetic complications, and neurodegeneration.”
BackgroundNF90 coordinately represses the senescence-associated secretory phenotype
Tominaga-Yamanaka, K., Abdelmohsen, K., Martindale, J. L., Yang, X., Taub, D. D., & Gorospe, M. (2012) · Aging · doi:10.18632/aging.100497 · Cited by 49 · cited 1×
“The senescent phenotype is characterized by a large, flat cell morphology (hypertrophy), cellular hyperfunctions such as hypersecretion and proinflammation, and an increased lysosomal activity and lipid accumulation.(24-33) Senescent cells have increased levels of cyclin D1.”
Background
Cited by
Autophagy maintains stemness by preventing senescence
García-Prat, L., Martínez-Vicente, M., Perdiguero, E., Ortet, L., Rodríguez-Ubreva, J., Rebollo, E., Ruiz-Bonilla, V., Gutarra, S., Ballestar, E., Serrano, A. L., et al. (2016) · Nature · doi:10.1038/nature16187 · Cited by 1,355
Geriatric muscle stem cells switch reversible quiescence into senescence
Sousa-Victor, P., Gutarra, S., García-Prat, L., Rodriguez-Ubreva, J., Ortet, L., Ruiz-Bonilla, V., Jardí, M., Ballestar, E., González, S., Serrano, A. L., et al. (2014) · Nature · doi:10.1038/nature13013 · Cited by 1,010
Skin cancer and new treatment perspectives: A review
Simões, M. C. F., Sousa, J. J. S., & Pais, A. A. C. C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.001 · Cited by 414
The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks
Aunan, J. R., Cho, W. C., & Søreide, K. (2017) · Aging and disease · doi:10.14336/ad.2017.0103 · Cited by 373
Moncsek, A., Al‐Suraih, M. S., Trussoni, C. E., O'Hara, S. P., Splinter, P. L., Zuber, C., Patsenker, E., Valli, P. V., Fingas, C. D., Weber, A., et al. (2018) · Hepatology · doi:10.1002/hep.29464 · Cited by 136
Metadata
- Authors
- Blagosklonny, M. V.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-12
- Volume
- 14
- Issue
- 12
- Pages
- 1092-1097
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2038055963
- Cited by
- 43
- References
- 32
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.